Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Endocrinology›Condition·Updated Jul 11, 2026·v1

Type 2 Diabetes Mellitus

Type 2 diabetes mellitus is a progressive metabolic disease driven by insulin resistance and beta-cell failure, with a global prevalence of over 537 million. Management has evolved from glucose-centric to complication-centric care, with SGLT2 inhibitors and GLP-1 receptor agonists now providing cardiorenal protection. Early diagnosis, lifestyle modification, metformin as first-line, and prompt addition of organ-protective agents in high-risk patients are essential to reduce microvascular and macrovascular complications. Age at diagnosis is the strongest risk stratifier, and treatment intensity should be individualized accordingly.

High Evidence404 references·11,456 words·46 min read·v1
type 2 diabetesdiabetes mellitusinsulin resistancemetforminSGLT2 inhibitorGLP-1 receptor agonistcardiorenal protectiondiabetic ketoacidosisprediabetes

Quick Reference

RxDrug of choiceMetformin 500-1000 mg twice daily (first-line for most patients without cardiorenal disease)
AltAlternativesSGLT2 inhibitors (empagliflozin 10-25 mg daily, canagliflozin 100 mg daily, dapagliflozin 10 mg daily); GLP-1 receptor agonists (liraglutide 1.8 mg daily, semaglutide 0.5-1.0 mg weekly, tirzepatide 2.5-15 mg weekly); DPP-4 inhibitors (sitagliptin 100 mg daily); basal insulin (glargine, degludec)
⊘AvoidMetformin if eGFR <30 mL/min/1.73 m²; saxagliptin in patients with heart failure; thiazolidinediones in NYHA class III-IV HF; SGLT2i should be held during acute illness or 24-72 h before elective surgery
DxTest of choiceHbA1c (≥6.5%) for initial diagnosis when not affected by hemoglobinopathies or anemia; 75-g OGTT with 2-hour glucose ≥200 mg/dL as gold standard for borderline cases
ScKey scoreWATCH-DM score for 5-year heart failure risk; age at diagnosis for overall mortality risk (each year earlier increases risk by 4%)
→When to referEndocrinology if atypical (lipodystrophy, monogenic diabetes, type 1/LADA uncertainty); nephrology if eGFR <30 or progressive albuminuria; ophthalmology for annual dilated eye exam or if retinopathy detected; bariatric surgery evaluation if BMI ≥35 (or ≥30 with poor control)
T2DM is a heterogeneous disease requiring early intensive glycemic control and cardiorenal protection; SGLT2 inhibitors and GLP-1 receptor agonists reduce major adverse cardiovascular events and slow CKD progression independent of glucose lowering.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder driven by progressive beta-cell dysfunction on a background of insulin resistance, affecting over 537 million adults worldwide. Management has shifted from a glucose-centric to a complication-centric paradigm: SGLT2 inhibitors and GLP-1 receptor agonists now provide organ protection independent of glycemic control, reducing heart failure hospitalizations by up to 50% and slowing CKD progression by 30%. Early detection, aggressive lifestyle modification, and individualized pharmacotherapy targeting glycemic, cardiovascular, and renal endpoints are essential to alter the disease trajectory and prevent long-term complications.

Overview and Recommendations

Background

  • •Type 2 diabetes mellitus (T2DM) is a heterogeneous syndrome defined by hyperglycemia resulting from progressive insulin resistance and beta-cell failure, accounting for approximately 90% of diabetes cases globally and affecting an estimated 537 million adults, a prevalence that has more than doubled in the past three decades.
  • •The pathophysiologic cascade involves five integrated defects: insulin resistance in liver, muscle, and adipose tissue; progressive beta-cell secretory dysfunction with 30-60% mass loss; alpha-cell glucagon dysregulation causing inappropriate hepatic glucose output; a blunted incretin axis (reduced GLP-1 secretion and impaired GIP response); and chronic low-grade inflammation driven by adipose-tissue macrophages, altered gut microbiota, and mitochondrial dysfunction.
  • •Data-driven clustering has identified five reproducible subtypes, severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), and mild age-related diabetes (MARD), which differ in age at diagnosis, BMI, complication risk (SIRD highest for nephropathy, SIDD for retinopathy), and therapeutic response.
  • •The landmark UKPDS and its 10-year follow-up (the legacy effect) demonstrated that early intensive glycemic control with sulfonylurea, insulin, or metformin reduced long-term myocardial infarction by 15% and all-cause mortality by 13%, establishing the principle that early metabolic memory determines future cardiovascular outcomes.
  • •The therapeutic revolution driven by SGLT2 inhibitors (CREDENCE: canagliflozin 100 mg daily reduced end-stage kidney disease by 32%, HR 0.68) and GLP-1 receptor agonists (LEADER: liraglutide 1.8 mg daily reduced cardiovascular death by 22%, HR 0.78) has moved the goal from glucose lowering to organ protection, with NNTs for cardiorenal outcomes as low as 18-56 over 2-4 years.
  • •Age at diagnosis is the single most powerful risk stratifier: each 1-year increase in age at diagnosis reduces all-cause mortality by 4%, macrovascular disease by 3%, and microvascular disease by 5%, meaning a patient diagnosed at age 40 carries substantially higher lifetime risk than one diagnosed at age 60, independent of current HbA1c.

Evaluation

  • •Suspect T2DM in any patient with classic symptoms (polyuria, polydipsia, unintentional weight loss), incidental hyperglycemia, or risk factors (age ≥45, BMI ≥25, family history, hypertension, history of gestational diabetes, PCOS, or South Asian ethnicity).
  • •Establish the diagnosis using any of the four ADA criteria: HbA1c ≥6.5% (48 mmol/mol), fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during a 75-g oral glucose tolerance test (OGTT), or random glucose ≥200 mg/dL (11.1 mmol/L) with classic symptoms; confirm with repeat testing unless unequivocal hyperglycemia is present.
  • •Order HbA1c as the first-line diagnostic test for most patients; when HbA1c is unreliable (hemoglobinopathy, anemia, CKD stage 4-5, pregnancy, recent transfusion), use fasting glucose or OGTT instead.
  • •If HbA1c or fasting glucose is borderline (5.7-6.4% or 100-125 mg/dL), perform a 75-g OGTT to classify prediabetes or overt diabetes; a 1-hour postload glucose ≥155 mg/dL (8.6 mmol/L) identifies individuals at high risk for progression even before HbA1c becomes abnormal.
  • •Assess the full metabolic profile: fasting lipid panel, liver function tests (with liver ultrasound or transient elastography if NAFLD suspected), serum creatinine and eGFR, urine albumin-to-creatinine ratio, thyroid-stimulating hormone, and vitamin D levels.
  • •Screen for microvascular complications at diagnosis: dilated eye examination for retinopathy, 10-g monofilament test and vibration sense for peripheral neuropathy, and urine ACR plus eGFR for nephropathy.
  • •Stratify cardiovascular risk using validated tools: the WATCH-DM score (integrating weight, age, hypertension, creatinine, HDL-C, fasting glucose, QRS duration, MI, and CABG history) predicts 5-year heart failure risk; age at diagnosis under 40 years identifies highest lifetime risk.
  • •Consider diabetes subtype in atypical presentations: low C-peptide in the setting of hyperglycemia suggests autoimmune diabetes (type 1 or LADA); insulin requirement >100 U/day in a non-obese patient should prompt evaluation for familial partial lipodystrophy (check LMNA and PPARG mutations).
  • •In women with PCOS, use a 75-g OGTT for screening rather than HbA1c or fasting glucose alone, as isolated fasting glucose misses up to one-third of glucose intolerance; in women with prior gestational diabetes, postpartum OGTT should never be deferred.
  • •Evaluate for common comorbidities: depression (PHQ-9, bidirectional risk with T2DM), obstructive sleep apnea (STOP-Bang), metabolic dysfunction-associated steatotic liver disease (MASLD, pooled prevalence ~57%), and hyperuricemia or gout (prevalence ~22%).
  • •In older adults, consider the BMI paradox, overweight (BMI ≥30) may appear protective but central obesity (waist circumference ≥100 cm men/≥95 cm women) predicts higher risk; screen for frailty, cognitive impairment, and hypoglycemia risk before setting glycemic targets.
  • •For hospitalized patients with hyperglycemia, measure HbA1c to distinguish newly diagnosed diabetes from stress hyperglycemia, and initiate basal-bolus insulin (glargine once daily plus rapid-acting before meals) over sliding-scale insulin to reduce postoperative complications.
  • •In patients on SGLT2 inhibitors presenting with nausea, vomiting, or unexplained acidosis, check serum ketones and the anion gap regardless of glucose level, euglycemic diabetic ketoacidosis is a treatable emergency that is missed when hyperglycemia is absent.

Management

  • •Initiate intensive lifestyle modification at diagnosis: goal of ≥150 minutes per week of moderate-to-vigorous physical activity, dietary counseling to achieve 5-10% weight loss, and behavioral support; time-restricted eating (20-hour fast/4-hour eating window) improves beta-cell function and reduces HbA1c by 0.32%.
  • •Start metformin as first-line pharmacotherapy for most patients: 500 mg orally twice daily, titrated to 1000 mg twice daily as tolerated; hold if eGFR falls below 30 mL/min/1.73 m²; monitor for gastrointestinal side effects and consider extended-release formulation.
  • •In patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), initiate an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit independent of baseline HbA1c or metformin use, these agents now share first-line status per the ADA/EASD 2022 consensus.
  • •Prescribe empagliflozin 10 mg once daily (target 25 mg) or canagliflozin 100 mg once daily or dapagliflozin 10 mg once daily for SGLT2i; educate patients about euglycemic DKA risk and to hold the medication during acute illness or before elective surgery (at least 24 hours, 72 hours for on-pump CABG).
  • •Initiate liraglutide 0.6 mg subcutaneously daily for one week, then increase by 0.6 mg weekly to a target dose of 1.8 mg daily; alternatively, start semaglutide 0.25 mg subcutaneously weekly for four weeks, then escalate to 0.5 mg weekly, and if needed to 1.0 mg weekly for glycemic and cardiovascular benefit.
  • •For dual GIP/GLP-1 receptor agonism, use tirzepatide 2.5 mg subcutaneously weekly for four weeks, then escalate by 2.5 mg every four weeks to a maximum of 15 mg weekly, the most effective agent for HbA1c reduction (mean -1.96% vs placebo) and weight loss (-9.57 kg).
  • •If additional glucose lowering is needed without cardiorenal indication, add a DPP-4 inhibitor (sitagliptin 100 mg once daily, reduced to 50 mg if eGFR 30-50, 25 mg if <30) or basal insulin; avoid saxagliptin due to increased heart failure hospitalization (HR 1.27).
  • •Initiate basal insulin when HbA1c remains >9.0% on oral triple therapy or if catabolic symptoms (weight loss, polyuria) are present: start insulin glargine 10 units once daily, titrate by 10-15% weekly to achieve fasting glucose 4.0-5.5 mmol/L; insulin degludec provides non-inferior control with less nocturnal hypoglycemia.
  • •For hospitalized patients requiring insulin, use a basal-bolus regimen (glargine once daily plus glulisine three times daily before meals) rather than sliding-scale insulin, this reduces the composite of wound infection, pneumonia, and acute renal failure (8.6% vs 24.3%, OR 3.39).
  • •Target an HbA1c <7.0% for most nonpregnant adults; consider <6.5% for young patients (<40 years) with short disease duration and no CVD; target <8.0% for older patients with limited life expectancy or advanced complications; reassess every 3-6 months.
  • •Manage cardiovascular risk concurrently: prescribe a statin to achieve LDL <70 mg/dL (or <55 mg/dL in very high-risk patients); use ACE inhibitor or ARB for hypertension and albuminuria; target blood pressure <130/80 mm Hg, with caution for intensive targets <120 mm Hg (stroke benefit but increased serious adverse events, NNH=50).
  • •Avoid routine combination of fenofibrate with statin, the ACCORD lipid trial showed no cardiovascular benefit (HR 0.92) and potential harm in women; use fenofibrate as monotherapy only in severe hypertriglyceridemia (triglycerides >500 mg/dL).
  • •In diabetic ketoacidosis (glucose >250 mg/dL, pH <7.3, bicarbonate <15, positive ketones): administer 0.9% saline at 15-20 mL/kg/hour IV (max 1.5 L in first hour), give IV regular insulin 0.1 U/kg bolus followed by 0.1 U/kg/hour continuous infusion, and monitor potassium every 2 hours; when glucose falls below 200 mg/dL, reduce insulin infusion rate to 0.02-0.05 U/kg/hour.
  • •Transition from IV to subcutaneous insulin in DKA only after the anion gap normalizes (≤12 mmol/L) and the patient is tolerating oral intake; administer basal insulin (e.g., glargine 0.2-0.3 U/kg) 2 hours before stopping the IV insulin infusion to prevent rebound hyperglycemia.
  • •Refer for metabolic surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) in patients with BMI ≥35 kg/m² or BMI ≥30 kg/m² with poorly controlled T2DM, remission rates of 60-80% at 1-2 years with durability up to 10 years, superior to medical therapy.
  • •In pregnancy, use insulin as first-line therapy; continuing metformin is reasonable but monitor for small-for-gestational-age infants; target fasting glucose <95 mg/dL, 1-hour postprandial <140 mg/dL, and 2-hour <120 mg/dL.
  • •In youth-onset T2DM, start metformin 500 mg twice daily (max 2000 mg) plus intensive lifestyle; add a GLP-1 receptor agonist (dulaglutide 0.75 mg weekly, titrate to 1.5 mg) if HbA1c remains above target.
  • •Screen and treat depression (PHQ-9 annually), depression doubles as a risk factor and a complication of T2DM; treatment improves glycemic control and quality of life.
  • •For primary prevention of T2DM in prediabetes: recommend lifestyle intervention (reduces incidence by 43%); consider metformin 500 mg twice daily or pioglitazone 15-45 mg daily (off-label, NNT=18 over 2.4 years) in high-risk individuals with impaired glucose tolerance.
  • •What NOT to do: do not use saxagliptin in patients at risk for heart failure; do not target systolic BP <120 mm Hg in elderly or frail patients; do not use sliding-scale insulin in hospitalized patients who are eating; do not use fenofibrate as add-on to statin for cardiovascular prevention.

Board Review — High Yield

  • •UKPDS legacy effect, Early intensive glycemic control reduces long-term MI by 15% and all-cause mortality by 13% despite early loss of HbA1c differences.
  • •CREDENCE trial, Canagliflozin 100 mg daily reduces end-stage kidney disease by 32% (HR 0.68) in albuminuric CKD patients.
  • •LEADER trial, Liraglutide 1.8 mg daily reduces cardiovascular death by 22% (HR 0.78) in high-risk T2DM.
  • •Diabetic ketoacidosis (DKA), Glucose >250 mg/dL, pH <7.3, bicarbonate <15, positive ketones; treat with IV fluids, IV insulin 0.1 U/kg bolus + 0.1 U/kg/h, and potassium repletion.
  • •Hyperosmolar hyperglycemic state (HHS), Glucose >600 mg/dL, osmolality >320 mOsm/kg, pH >7.3; higher mortality than DKA (~15%).
  • •Metformin, Inhibits hepatic gluconeogenesis; first-line therapy; reduces MI by 33% in overweight UKPDS subgroup; contraindicated if eGFR <30.
  • •Incretin axis defect, Reduced GLP-1 secretion and impaired GIP action in T2DM lead to blunted glucose-stimulated insulin secretion and hyperglucagonemia.
  • •Screening in PCOS, OGTT is preferred over HbA1c because isolated fasting glucose misses ~33% of glucose intolerance.
  • •Age at diagnosis as risk stratifier, Each 1-year earlier diagnosis increases mortality risk by 4% and microvascular disease by 5%.
  • •Prediabetes prevention, Lifestyle intervention reduces T2DM incidence by 43% (RR 0.57); pioglitazone reduces conversion by 72% (HR 0.28; NNT=18).

Deep Dive — Evidence Details

References

  1. [1]

    Fassnacht M, Arlt W, Bancos I et al.. “Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.” European journal of endocrinology (2016). PMID: 27390021 ↗

    L1GUIDELINECited in: Definition, Classification and Axis Nomenclature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  2. [2]

    Balasubramanian P, Wanner C, Ferreira JP et al.. “Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?” The Journal of clinical endocrinology and metabolism (2022). PMID: 35290464 ↗

    L1RCTCited in: Definition, Classification and Axis Nomenclature, History and Evolution of Treatment
  3. [3]

    Raz I, Ceriello A, Wilson PW et al.. “Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia.” Diabetes care (2011). PMID: 21593301 ↗

    L2RCTCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  4. [4]

    Tanabe H, Hirai H, Saito H et al.. “Detecting Sarcopenia Risk by Diabetes Clustering: A Japanese Prospective Cohort Study.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35908291 ↗

    L2COHORTCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  5. [5]

    Ebeling PR, Adler RA, Jones G et al.. “MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of Vitamin D.” European journal of endocrinology (2018). PMID: 30131372 ↗

    L5SR_OBSCited in: Definition, Classification and Axis Nomenclature, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  6. [6]

    Beulens JW, Patel A, Vingerling JR et al.. “Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.” Diabetologia (2009). PMID: 19633827 ↗

    L1RCTCited in: Definition, Classification and Axis Nomenclature
  7. [7]

    Ollila MM, Arffman RK, Korhonen E et al.. “Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria-a prospective population-based cohort study.” European journal of endocrinology (2023). PMID: 37436934 ↗

    L2COHORTCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  8. [8]

    Bellamy L, Casas JP, Hingorani AD et al.. “Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis.” Lancet (London, England) (2009). PMID: 19465232 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Special Populations, Pregnancy and Fertility
  9. [9]

    Hoek AG, Dal Canto E, Wenker E et al.. “Epidemiology of heart failure in diabetes: a disease in disguise.” Diabetologia (2024). PMID: 38334818 ↗

    L5SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  10. [10]

    Nouwen A, Winkley K, Twisk J et al.. “Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis.” Diabetologia (2010). PMID: 20711716 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors
  11. [11]

    Gurgoglione FL, Pitocco D, Montone RA et al.. “Microvascular Complications Are Associated With Coronary Collateralization in Type 2 Diabetes and Chronic Occlusion.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37417706 ↗

    L3OTHERCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  12. [12]

    Golden SH, Brown A, Cauley JA et al.. “Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22730516 ↗

    L5OTHERCited in: Definition, Classification and Axis Nomenclature
  13. [13]

    Zeitler P. “Update on nonautoimmune diabetes in children.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19584196 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature
  14. [14]

    Yin T, Kuo SC, Chang YY et al.. “Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28368479 ↗

    L2OTHERCited in: Definition, Classification and Axis Nomenclature
  15. [15]

    Hiersch L, Shah BR, Berger H et al.. “Oral Glucose Tolerance Test Results in Pregnancy Can Be Used to Individualize the Risk of Future Maternal Type 2 Diabetes Mellitus in Women With Gestational Diabetes Mellitus.” Diabetes care (2021). PMID: 34131049 ↗

    L2OTHERCited in: Definition, Classification and Axis Nomenclature, Special Populations, Pregnancy and Fertility
  16. [16]

    Bianchi C, Miccoli R, Bonadonna RC et al.. “Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance.” Diabetes care (2012). PMID: 22912427 ↗

    L4OTHERCited in: Definition, Classification and Axis Nomenclature
  17. [17]

    Zhang J, Lin Z, Zhong S et al.. “Traditional Chinese medicine syndrome patterns and associated factors in adults with type 2 diabetes and metabolic syndrome: a data-driven analysis.” Frontiers in endocrinology (2026). PMID: 42388871 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification and Axis Nomenclature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  18. [18]

    Leslie RD, Palmer J, Schloot NC et al.. “Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment.” Diabetologia (2016). PMID: 26498592 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  19. [19]

    Mori T, Zaharia OP, Straßburger K et al.. “Recognising, quantifying and accounting for classification uncertainty in type 2 diabetes subtypes.” Diabetologia (2025). PMID: 40715719 ↗

    L4OTHERCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  20. [20]

    Kostev K, Rathmann W. “Diabetic retinopathy at diagnosis of type 2 diabetes in the UK: a database analysis.” Diabetologia (2012). PMID: 23052061 ↗

    L4OTHERCited in: Definition, Classification and Axis Nomenclature
  21. [21]

    de Victoria Carazo JM, Guirao Arrabal E, Montero-Alonso MÁ et al.. “Incidence, mortality and risk factors in COVID-19-associated pulmonary aspergillosis (CAPA): an umbrella review and meta-meta-analyses (2020-2025).” Respiratory medicine (2026). PMID: 42302999 ↗

    L2SR_OBSCited in: Definition, Classification and Axis Nomenclature, Acute Management and Endocrine Emergencies
  22. [22]

    Rodriguez-Hilarion JA, Ramos-Castaneda JA, Duran Aguero S et al.. “Effect of Ultra-Processed Foods Consumption on Human Health Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses.” Nutrition reviews (2026). PMID: 42247240 ↗

    L2SR_OBSCited in: Definition, Classification and Axis Nomenclature
  23. [23]

    Chen A, Zhao K, Ceban F et al.. “Glucagon-like peptide-1 receptor agonists and gastric emptying time: a systematic review and meta-analysis of prospective studies.” Canadian journal of anaesthesia = Journal canadien d'anesthesie (2026). PMID: 42087044 ↗

    L2SR_OBSCited in: Definition, Classification and Axis Nomenclature
  24. [24]

    White RT, Henriquez P, Innocent B et al.. “Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review.” Pharmacotherapy (2026). PMID: 41947645 ↗

    L2SR_OBSCited in: Definition, Classification and Axis Nomenclature
  25. [25]

    Wang X, You S, Tang S et al.. “Depression comorbidity in children and adolescents with type 2 diabetes mellitus: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41918972 ↗

    L2SR_OBSCited in: Definition, Classification and Axis Nomenclature
  26. [26]

    Richter B, Hemmingsen B, Metzendorf MI et al.. “Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.” The Cochrane database of systematic reviews (2018). PMID: 30371961 ↗

    L2SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Prognosis, Natural History and Prevention
  27. [27]

    Hemmingsen B, Gimenez-Perez G, Mauricio D et al.. “Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2017). PMID: 29205264 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  28. [28]

    Chew BH, Vos RC, Metzendorf MI et al.. “Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2017). PMID: 28954185 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  29. [29]

    Hemmingsen B, Schroll JB, Lund SS et al.. “Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2013). PMID: 23633364 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
  30. [30]

    Rolim LC, da Silva EM, Flumignan RL et al.. “Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy.” The Cochrane database of systematic reviews (2019). PMID: 31201734 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification, History and Evolution of Treatment
  31. [31]

    Hemmingsen B, Lund SS, Gluud C et al.. “Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2011). PMID: 21678374 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
  32. [32]

    Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40652453 ↗

    L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  33. [33]

    Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” European journal of endocrinology (2025). PMID: 40652450 ↗

    L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  34. [34]

    Hartman ML, Sanyal AJ, Loomba R et al.. “Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.” Diabetes care (2020). PMID: 32291277 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  35. [35]

    Burggraaf B, Pouw NMC, Fernández Arroyo S et al.. “Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus.” European journal of endocrinology (2022). PMID: 35312632 ↗

    L2RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  36. [36]

    Grey A, Bolland M, Fenwick S et al.. “The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial.” European journal of endocrinology (2013). PMID: 24217934 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
  37. [37]

    Piccoli GF, Mesquita LA, Stein C et al.. “Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33248445 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  38. [38]

    Pinto LC, Rados DV, Remonti LR et al.. “Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32797182 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Special Populations, Pregnancy and Fertility
  39. [39]

    Mantovani A, Morandin R, Lando MG et al.. “Sodium-Glucose Cotransporter 2 Inhibitor Use and Risk of Liver-Related Events in Patients With Type 2 Diabetes: A Meta-analysis of Observational Cohort Studies.” Diabetes care (2025). PMID: 40392994 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors
  40. [40]

    Francque SM, Bedossa P, Ratziu V et al.. “A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.” The New England journal of medicine (2021). PMID: 34670042 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  41. [41]

    Arslanian SA, Hannon T, Zeitler P et al.. “Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.” The New England journal of medicine (2022). PMID: 35658022 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
  42. [42]

    Larsen CM, Faulenbach M, Vaag A et al.. “Interleukin-1-receptor antagonist in type 2 diabetes mellitus.” The New England journal of medicine (2007). PMID: 17429083 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  43. [43]

    Solomon SD, Uno H, Lewis EF et al.. “Erythropoietic response and outcomes in kidney disease and type 2 diabetes.” The New England journal of medicine (2010). PMID: 20843249 ↗

    L2RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  44. [44]

    Ray KK, Seshasai SR, Wijesuriya S et al.. “Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.” Lancet (London, England) (2009). PMID: 19465231 ↗

    L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  45. [45]

    Morales DR, Bu F, Viernes B et al.. “Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study.” Diabetes care (2025). PMID: 40465422 ↗

    L3COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  46. [46]

    Anthony MS, Aroda VR, Parlett LE et al.. “Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.” Diabetes care (2024). PMID: 38363873 ↗

    L3COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  47. [47]

    Bakker LE, Sleddering MA, Schoones JW et al.. “Pathogenesis of type 2 diabetes in South Asians.” European journal of endocrinology (2013). PMID: 23939919 ↗

    L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  48. [48]

    Karagiannis T, Malandris K, Avgerinos I et al.. “Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.” Diabetologia (2024). PMID: 38613667 ↗

    L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  49. [49]

    Burant CF, Viswanathan P, Marcinak J et al.. “TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2012). PMID: 22374408 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  50. [50]

    Keech AC, Mitchell P, Summanen PA et al.. “Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.” Lancet (London, England) (2007). PMID: 17988728 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors
  51. [51]

    Pratley RE, Nauck M, Bailey T et al.. “Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.” Lancet (London, England) (2010). PMID: 20417856 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  52. [52]

    Zhu D, Ma J, Wang W et al.. “Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.” Diabetologia (2025). PMID: 41272211 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, History and Evolution of Treatment
  53. [53]

    Zhou Z, Jardine M, Perkovic V et al.. “Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.” Diabetologia (2019). PMID: 31399845 ↗

    L2RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
  54. [54]

    Kuss O, Opitz ME, Brandstetter LV et al.. “How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials.” Diabetologia (2023). PMID: 37338539 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
  55. [55]

    Kramer CK, Zinman B, Retnakaran R. “Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis.” The lancet. Diabetes & endocrinology (2013). PMID: 24622264 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History and Prevention
  56. [56]

    Houghton D, Hardy T, Stewart C et al.. “Systematic review assessing the effectiveness of dietary intervention on gut microbiota in adults with type 2 diabetes.” Diabetologia (2018). PMID: 29754286 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  57. [57]

    Salama M, Balagopal B, Fennoy I et al.. “Childhood Obesity, Diabetes. and Cardiovascular Disease Risk.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37319430 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  58. [58]

    Pohlman N, Patel PN, Essien UR et al.. “Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40388382 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  59. [59]

    Kasher Meron M, Hornik-Lurie T, Twig G et al.. “GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41665888 ↗

    L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  60. [60]

    Chia CW, Egan JM. “Incretin-based therapies in type 2 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18628530 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  61. [61]

    Rottenkolber M, Gar C, Then C et al.. “A Pathophysiology of Type 2 Diabetes Unrelated to Metabolic Syndrome.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33515032 ↗

    L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  62. [62]

    Tong J, Li N, Hu F et al.. “Metabolic Improvement Mediates the Causal Relationship Between GLP-1 Receptor Agonists and Myocardial Infarction: A Mendelian Randomization and Mediation Analysis Study.” Diabetes care (2026). PMID: 41259721 ↗

    L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
  63. [63]

    Gonzalez JS, Bebu I, Krause-Steinrauf H et al.. “Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).” Diabetes care (2024). PMID: 38416773 ↗

    L1OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  64. [64]

    Bolli GB, Home PD, Porcellati F et al.. “The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes.” Diabetes care (2025). PMID: 40116796 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  65. [65]

    Chakkera HA, Weil EJ, Pham PT et al.. “Can new-onset diabetes after kidney transplant be prevented?” Diabetes care (2013). PMID: 23613600 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  66. [66]

    Tian L, Li X, Zeng X et al.. “Increased Thyroid Hormone Action Alleviates Hippocampal Damage by Downregulating Neuronal Type I Interferon Signaling/Necroptosis in Diabetes-Associated Cognitive Dysfunction.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 39104259 ↗

    L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  67. [67]

    Alonso-Ventura V, Civeira F, Alvarado-Rosas A et al.. “A Cross-Sectional Study Examining the Parametric Thyroid Feedback Quantile Index and Its Relationship with Metabolic and Cardiovascular Diseases.” Thyroid : official journal of the American Thyroid Association (2022). PMID: 35891590 ↗

    L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
  68. [68]

    González-Luis A, Llinares-Arvelo V, Martínez-Alberto CE et al.. “Glucagon-like peptide-1 receptor agonists and muscle health: potential role in sarcopenia prevention and treatment.” European journal of endocrinology (2025). PMID: 41166543 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  69. [69]

    Allin KH, Nielsen T, Pedersen O. “Mechanisms in endocrinology: Gut microbiota in patients with type 2 diabetes mellitus.” European journal of endocrinology (2014). PMID: 25416725 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  70. [70]

    Kurstjens S, de Baaij JH, Bouras H et al.. “Determinants of hypomagnesemia in patients with type 2 diabetes mellitus.” European journal of endocrinology (2016). PMID: 27707767 ↗

    L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  71. [71]

    Van Gaal LF, Gutkin SW, Nauck MA. “Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?” European journal of endocrinology (2008). PMID: 18322302 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  72. [72]

    Emara A, Emara M, Mansour A et al.. “Efficacy and safety of orforglipron in obesity with type 2 diabetes mellitus: a GRADE-assessed meta-analysis of randomized controlled trials.” Diabetology & metabolic syndrome (2026). PMID: 42363271 ↗

    L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  73. [73]

    Rosen CJ, Ingelfinger JR. “GLP-1 Receptor Agonists.” The New England journal of medicine (2026). PMID: 41931049 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  74. [74]

    Jun JE, Oh DH, Jeong IK et al.. “Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses.” Frontiers in endocrinology (2026). PMID: 42388875 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
  75. [75]

    Wu X, Yang Y, Cui X et al.. “Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.” Frontiers in pharmacology (2026). PMID: 42394981 ↗

    L1TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  76. [76]

    Sanchez-Rangel E, Inzucchi SE. “Metformin: clinical use in type 2 diabetes.” Diabetologia (2017). PMID: 28770321 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  77. [77]

    Davies MJ, Aroda VR, Collins BS et al.. “Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).” Diabetologia (2022). PMID: 36151309 ↗

    L1REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  78. [78]

    Vergès B. “Pathophysiology of diabetic dyslipidaemia: where are we?” Diabetologia (2015). PMID: 25725623 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  79. [79]

    Sun WT, Liu RX, Jiang YH et al.. “Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.” Diabetes, obesity & metabolism (2026). PMID: 42426564 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  80. [80]

    Caruso P, Di Martino N, Longo M et al.. “Glucagon-like peptide-1 receptor agonists and major limb events in adults with type 2 diabetes and peripheral artery disease: a systematic review and meta-analysis of RCTs and cohort studies.” Cardiovascular diabetology (2026). PMID: 42410649 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  81. [81]

    Li R, Zhao X, Shen J et al.. “Glucagon-like peptide-1 receptor agonist use and risk of gynecologic cancers: a meta-analysis of multinational real-world cohort studies.” Preventive medicine reports (2026). PMID: 42381894 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  82. [82]

    Soliman AT, Alyafei F, Khalil A et al.. “GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.” Diabetes research and clinical practice (2026). PMID: 42365860 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  83. [83]

    Mohammadi D, Sadeghirad B, Rasouli MA et al.. “Comparative cardiovascular efficacy of antidiabetic therapies in type 2 diabetes: a systematic review and network meta-analysis of randomized trials.” Diabetology & metabolic syndrome (2026). PMID: 42365335 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  84. [84]

    Kautzky-Willer A, Harreiter J, Pacini G. “Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus.” Endocrine reviews (2016). PMID: 27159875 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  85. [85]

    Cornier MA, Dabelea D, Hernandez TL et al.. “The metabolic syndrome.” Endocrine reviews (2008). PMID: 18971485 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  86. [86]

    Kodl CT, Seaquist ER. “Cognitive dysfunction and diabetes mellitus.” Endocrine reviews (2008). PMID: 18436709 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  87. [87]

    Donath MY, Meier DT, Böni-Schnetzler M. “Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease.” Endocrine reviews (2019). PMID: 31127805 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  88. [88]

    Patti ME, Corvera S. “The role of mitochondria in the pathogenesis of type 2 diabetes.” Endocrine reviews (2010). PMID: 20156986 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors
  89. [89]

    Ussher JR, Drucker DJ. “Cardiovascular biology of the incretin system.” Endocrine reviews (2012). PMID: 22323472 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  90. [90]

    Meijnikman AS, Gerdes VE, Nieuwdorp M et al.. “Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans.” Endocrine reviews (2018). PMID: 29309555 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  91. [91]

    Abdul-Ghani MA, Norton L, Defronzo RA. “Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.” Endocrine reviews (2011). PMID: 21606218 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  92. [92]

    Pal K, Eastwood SV, Michie S et al.. “Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2013). PMID: 23543567 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  93. [93]

    Kanie T, Mizuno A, Takaoka Y et al.. “Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.” The Cochrane database of systematic reviews (2021). PMID: 34693515 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  94. [94]

    El Dib R, Gameiro OL, Ogata MS et al.. “Zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance.” The Cochrane database of systematic reviews (2015). PMID: 26020622 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  95. [95]

    Richter B, Bandeira-Echtler E, Bergerhoff K et al.. “Rosiglitazone for type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2007). PMID: 17636824 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors
  96. [96]

    Richter B, Bandeira-Echtler E, Bergerhoff K et al.. “Pioglitazone for type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2006). PMID: 17054272 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  97. [97]

    Beletate V, El Dib RP, Atallah AN. “Zinc supplementation for the prevention of type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2007). PMID: 17253560 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  98. [98]

    Valentine N, Van de Laar FA, van Driel ML. “Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2012). PMID: 23152231 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  99. [99]

    Osman AA, Tayeb BA, Metzendorf MI et al.. “Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors combination therapy for adults with type 2 diabetes mellitus: a network meta-analysis.” The Cochrane database of systematic reviews (2025). PMID: 40237224 ↗

    L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  100. [100]

    Pitta FG, Lima EG, Tavares CAM et al.. “Empagliflozin in Patients With Type 2 Diabetes Undergoing On-Pump CABG: The POST-CABGDM Randomized Clinical Trial.” Diabetes care (2025). PMID: 40233024 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  101. [101]

    Ye W, Xu L, Ye Y et al.. “Efficacy and Safety of Meal Replacement in Patients With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37192345 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  102. [102]

    Barbarawi M, Zayed Y, Barbarawi O et al.. “Effect of Vitamin D Supplementation on the Incidence of Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32491181 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  103. [103]

    Gershkowitz BD, Hillert CJ, Crotty BH. “Digital Coaching Strategies to Facilitate Behavioral Change in Type 2 Diabetes: A Systematic Review.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33206975 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History and Prevention
  104. [104]

    Llamosas-Falcón L, Rehm J, Bright S et al.. “The Relationship Between Alcohol Consumption, BMI, and Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis.” Diabetes care (2023). PMID: 37890103 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  105. [105]

    Cummings DE, Cohen RV. “Bariatric/Metabolic Surgery to Treat Type 2 Diabetes in Patients With a BMI <35 kg/m2.” Diabetes care (2016). PMID: 27222550 ↗

    L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  106. [106]

    Inagaki N, Onouchi H, Sano H et al.. “SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.” The lancet. Diabetes & endocrinology (2013). PMID: 24622716 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  107. [107]

    Marso SP, Daniels GH, Brown-Frandsen K et al.. “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.” The New England journal of medicine (2016). PMID: 27295427 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  108. [108]

    Duckworth W, Abraira C, Moritz T et al.. “Glucose control and vascular complications in veterans with type 2 diabetes.” The New England journal of medicine (2008). PMID: 19092145 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  109. [109]

    Steg PG, Bhatt DL, Simon T et al.. “Ticagrelor in Patients with Stable Coronary Disease and Diabetes.” The New England journal of medicine (2019). PMID: 31475798 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors
  110. [110]

    Gaede P, Lund-Andersen H, Parving HH et al.. “Effect of a multifactorial intervention on mortality in type 2 diabetes.” The New England journal of medicine (2008). PMID: 18256393 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors
  111. [111]

    DeFronzo RA, Tripathy D, Schwenke DC et al.. “Pioglitazone for diabetes prevention in impaired glucose tolerance.” The New England journal of medicine (2011). PMID: 21428766 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
  112. [112]

    Bosch J, Gerstein HC, Dagenais GR et al.. “n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.” The New England journal of medicine (2012). PMID: 22686415 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors
  113. [113]

    Yu J, Kim B, Han K et al.. “Diabetes Progression and Its Impact on Kidney Cancer Risk: Insights From a Longitudinal Korean Cohort Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40459059 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors
  114. [114]

    Carey IM, Critchley JA, DeWilde S et al.. “Risk of Infection in Type 1 and Type 2 Diabetes Compared With the General Population: A Matched Cohort Study.” Diabetes care (2018). PMID: 29330152 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  115. [115]

    Anagnostis P, Christou K, Artzouchaltzi AM et al.. “Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis.” European journal of endocrinology (2019). PMID: 30400047 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  116. [116]

    Wang B, Xu D, Jing Z et al.. “Effect of long-term exposure to air pollution on type 2 diabetes mellitus risk: a systemic review and meta-analysis of cohort studies.” European journal of endocrinology (2014). PMID: 25298376 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  117. [117]

    Kawamori R, Tajima N, Iwamoto Y et al.. “Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.” Lancet (London, England) (2009). PMID: 19395079 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History and Prevention
  118. [118]

    Rajamani K, Colman PG, Li LP et al.. “Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.” Lancet (London, England) (2009). PMID: 19465233 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  119. [119]

    Zinman B, Harris SB, Neuman J et al.. “Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.” Lancet (London, England) (2010). PMID: 20605202 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
  120. [120]

    Bretzel RG, Nuber U, Landgraf W et al.. “Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.” Lancet (London, England) (2008). PMID: 18374840 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors
  121. [121]

    Exalto LG, Biessels GJ, Karter AJ et al.. “Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study.” The lancet. Diabetes & endocrinology (2013). PMID: 24622366 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  122. [122]

    Kramer CK, Campbell S, Retnakaran R. “Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis.” Diabetologia (2019). PMID: 30843102 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  123. [123]

    Smith AD, Crippa A, Woodcock J et al.. “Physical activity and incident type 2 diabetes mellitus: a systematic review and dose-response meta-analysis of prospective cohort studies.” Diabetologia (2016). PMID: 27747395 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  124. [124]

    Knol MJ, Twisk JW, Beekman AT et al.. “Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis.” Diabetologia (2006). PMID: 16520921 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History and Prevention
  125. [125]

    Mikłosz A, Chabowski A. “Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36916961 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  126. [126]

    Zhao H, Zhang B, Zhuo L et al.. “Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors and Epilepsy: A Population-Based Study Using Target Trial Emulation.” Diabetes care (2025). PMID: 40131448 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  127. [127]

    Jun JE, Jee JH, Bae JC et al.. “Association Between Changes in Thyroid Hormones and Incident Type 2 Diabetes: A Seven-Year Longitudinal Study.” Thyroid : official journal of the American Thyroid Association (2016). PMID: 27809684 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  128. [128]

    Galazis N, Afxentiou T, Xenophontos M et al.. “Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome.” European journal of endocrinology (2013). PMID: 23093701 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  129. [129]

    Anagnostis P, Majeed A, Johnston DG et al.. “Cardiovascular risk in women with type 2 diabetes mellitus and prediabetes: is it indeed higher than men?” European journal of endocrinology (2014). PMID: 25117464 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
  130. [130]

    Ittermann T, Markus MR, Schipf S et al.. “Metformin inhibits goitrogenous effects of type 2 diabetes.” European journal of endocrinology (2013). PMID: 23572084 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  131. [131]

    Kautzky-Willer A, Leutner M, Harreiter J. “Sex differences in type 2 diabetes.” Diabetologia (2023). PMID: 36897358 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  132. [132]

    Gao L, Ye G, Liu C et al.. “Prevalence and risk factors of hyperuricemia and gout in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 42422434 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  133. [133]

    Michels D, Walter C, Grathwohl-Karl A et al.. “Type 2 diabetes prevention programs at the community and municipal level: a scoping review of controlled intervention studies.” BMC public health (2026). PMID: 42387346 ↗

    L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  134. [134]

    Bray GA, Heisel WE, Afshin A et al.. “The Science of Obesity Management: An Endocrine Society Scientific Statement.” Endocrine reviews (2018). PMID: 29518206 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  135. [135]

    Di Pino A, DeFronzo RA. “Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.” Endocrine reviews (2019). PMID: 31050706 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  136. [136]

    Randeva HS, Tan BK, Weickert MO et al.. “Cardiometabolic aspects of the polycystic ovary syndrome.” Endocrine reviews (2012). PMID: 22829562 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  137. [137]

    Gupta N, Goel K, Shah P et al.. “Childhood obesity in developing countries: epidemiology, determinants, and prevention.” Endocrine reviews (2012). PMID: 22240243 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History and Prevention
  138. [138]

    Peer N, Balakrishna Y, Durao S. “Screening for type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2020). PMID: 32470201 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  139. [139]

    Naude CE, Brand A, Schoonees A et al.. “Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk.” The Cochrane database of systematic reviews (2022). PMID: 35088407 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  140. [140]

    Motuhifonua SK, Lin L, Alsweiler J et al.. “Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes.” The Cochrane database of systematic reviews (2023). PMID: 36790138 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  141. [141]

    Astavans A, Baughman D, Mathioudakis N. “Long-Term Major Adverse Cardiovascular and Cerebrovascular Event Risk in Adult-Onset Type 1 Versus Type 2 Diabetes: A Propensity-Matched Cohort Study.” European journal of preventive cardiology (2026). PMID: 42429688 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  142. [142]

    Wang M, Tipping O, Liu B et al.. “New-Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank.” International journal of cancer (2026). PMID: 42424092 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  143. [143]

    Gu L, Yang J, Shen J et al.. “Biological aging and the incidence and progression of diabetic retinopathy and kidney disease in type 2 diabetes mellitus: A prospective cohort study.” Diabetes research and clinical practice (2026). PMID: 42419488 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  144. [144]

    Park SM, Ko AJ, Lim JH et al.. “Income level and the risk of incident dementia among adults aged ≥50 with newly diagnosed type 2 diabetes: a population-based cohort study using the NHIS-Senior database in South Korea.” BMJ open (2026). PMID: 42409396 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
  145. [145]

    Lee SH, Lee KS, Lee JY et al.. “Impact of gestational diabetes on future diabetic retinopathy and microvascular complications: a nationwide cohort study.” BMC medicine (2026). PMID: 42399945 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Complications and Long-term Sequelae
  146. [146]

    Katznelson L. “Approach to the patient with persistent acromegaly after pituitary surgery.” The Journal of clinical endocrinology and metabolism (2010). PMID: 20823464 ↗

    L5CASE_REPORTCited in: Clinical Presentation
  147. [147]

    Tsang VHM, McGrath RT, Clifton-Bligh RJ et al.. “Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31265074 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  148. [148]

    Xin H, Fu Y, Feng M et al.. “Altered Intrinsic Brain Activity Related to Neurologic and Motor Dysfunction in Diabetic Peripheral Neuropathy Patients.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36333998 ↗

    L3OTHERCited in: Clinical Presentation
  149. [149]

    Xin A, Mizukami H, Inaba W et al.. “Pancreas Atrophy and Islet Amyloid Deposition in Patients With Elderly-Onset Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28505316 ↗

    L3OTHERCited in: Clinical Presentation
  150. [150]

    Gong S, Guo J, Han X et al.. “Clinical and Genetic Features of Patients With Type 2 Diabetes and Renal Glycosuria.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28324025 ↗

    L3OTHERCited in: Clinical Presentation
  151. [151]

    Smith RJ, Nathan DM, Arslanian SA et al.. “Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know.” The Journal of clinical endocrinology and metabolism (2010). PMID: 20194712 ↗

    L5OTHERCited in: Clinical Presentation
  152. [152]

    Sahu RP, Aggarwal A, Zaidi G et al.. “Etiology of early-onset type 2 diabetes in Indians: islet autoimmunity and mutations in hepatocyte nuclear factor 1alpha and mitochondrial gene.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17440016 ↗

    L3OTHERCited in: Clinical Presentation
  153. [153]

    Eldor R, Klieger Y, Sade-Feldman M et al.. “CD247, a novel T cell-derived diagnostic and prognostic biomarker for detecting disease progression and severity in patients with type 2 diabetes.” Diabetes care (2014). PMID: 25368105 ↗

    L3OTHERCited in: Clinical Presentation
  154. [154]

    Alsaigh T, Dhaliwal G, Fukaya E et al.. “An Alternate Explanation.” The New England journal of medicine (2023). PMID: 37018496 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  155. [155]

    Grossmann M, Anawalt BD, Yeap BB. “Testosterone therapy in older men: clinical implications of recent landmark trials.” European journal of endocrinology (2024). PMID: 38917356 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  156. [156]

    Palmieri S, Morelli V, Polledri E et al.. “The role of salivary cortisol measured by liquid chromatography-tandem mass spectrometry in the diagnosis of subclinical hypercortisolism.” European journal of endocrinology (2013). PMID: 23211572 ↗

    L2OTHERCited in: Clinical Presentation
  157. [157]

    Ziegler TR. “Parenteral nutrition in the critically ill patient.” The New England journal of medicine (2009). PMID: 19741230 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  158. [158]

    Miller RA, Birnbaum MJ. “Glucagon: acute actions on hepatic metabolism.” Diabetologia (2016). PMID: 27115415 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute Management and Endocrine Emergencies
  159. [159]

    Bonora E, Corrao G, Bagnardi V et al.. “Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus.” Diabetologia (2006). PMID: 16532323 ↗

    L2OTHERCited in: Clinical Presentation
  160. [160]

    Labad J, Price JF, Strachan MW et al.. “Symptoms of depression but not anxiety are associated with central obesity and cardiovascular disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.” Diabetologia (2009). PMID: 20012009 ↗

    L2OTHERCited in: Clinical Presentation
  161. [161]

    Visser ME, Kropman E, Kranendonk ME et al.. “Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C).” Diabetologia (2011). PMID: 21479595 ↗

    L4OTHERCited in: Clinical Presentation
  162. [162]

    Mikkelsen R, Larsen JB, Smidt K. “Association between Sex and Platelet Function in Patients with Diabetes Mellitus Type II: A Systematic Review.” Seminars in thrombosis and hemostasis (2026). PMID: 42263761 ↗

    L2SR_OBSCited in: Clinical Presentation, History and Evolution of Treatment
  163. [163]

    Mirmosayyeb O, Shaygannejad A, Vaheb S et al.. “Type 2 diabetes mellitus in people with multiple sclerosis: a systematic review and meta-analysis.” Acta neurologica Belgica (2026). PMID: 41975171 ↗

    L2SR_OBSCited in: Clinical Presentation
  164. [164]

    Paz-Pacheco E, Oliva RV, Acuin CS et al.. “Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Renal, Metabolic, Nutritional, and Endocrine Disorders.” Acta medica Philippina (2026). PMID: 42382928 ↗

    L1GUIDELINECited in: Clinical Presentation, Severity, Staging and Risk Stratification
  165. [165]

    Xiang Y, Fan B, Liu B. “Abdominal wall abscess due to Mycolicibacterium neworleansense: a case report.” BMC infectious diseases (2026). PMID: 42380938 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  166. [166]

    Liang H, Mao ZF, Huang JY et al.. “Case Report: Moxibustion-induced burns leading to disseminated methicillin-resistant Staphylococcus aureus infection in a patient with type 2 diabetes mellitus.” Frontiers in endocrinology (2026). PMID: 42272806 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  167. [167]

    Xu Y, Wang L, Li H et al.. “Mycobacterium abscessus bacteremia complicated by sepsis and septic shock in a patient with multiple comorbidities: a case report.” Frontiers in immunology (2026). PMID: 42183259 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  168. [168]

    Bai H, Yu J, Wang T et al.. “Case Report: A novel likely pathogenic GCK variant in a young Chinese girl with severe insulin resistance.” Frontiers in endocrinology (2026). PMID: 42137361 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  169. [169]

    Uhl S, Choure A, Rouse B et al.. “Effectiveness of Continuous Glucose Monitoring on Metrics of Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37987208 ↗

    L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  170. [170]

    Fassnacht M, Tsagarakis S, Terzolo M et al.. “European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.” European journal of endocrinology (2023). PMID: 37318239 ↗

    L1GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  171. [171]

    Kramer CK, Zinman B, Feig DS et al.. “Effect of Time-Restricted Eating on β-Cell Function in Adults With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39193706 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  172. [172]

    Robledo KP, Marschner IC, Handelsman DJ et al.. “Mediation analysis of the testosterone treatment effect to prevent type 2 diabetes in the Testosterone for Prevention of Type 2 Diabetes Mellitus trial.” European journal of endocrinology (2023). PMID: 37406250 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
  173. [173]

    Grey A, Beckley V, Doyle A et al.. “Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial.” European journal of endocrinology (2012). PMID: 22408124 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  174. [174]

    Flachs Madsen LR, Gerdøe-Kristensen S, Lauenborg J et al.. “Long-Term Follow-Up on Morbidity Among Women With a History of Gestational Diabetes Mellitus: A Systematic Review.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35763540 ↗

    L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  175. [175]

    Hespanhol LC, Agarwal S, Carvalhal G et al.. “Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.” Diabetes care (2026). PMID: 41940799 ↗

    L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  176. [176]

    Qiang J, Pathmaraj M, Lo T et al.. “The Effectiveness of Diabetes Prevention Programs Delivered in Primary Care for Individuals With Prediabetes or at Risk of Developing Type 2 Diabetes: A Systematic Review and Meta-analysis.” Diabetes care (2026). PMID: 42030121 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
  177. [177]

    Gyldenkerne C, Kahlert J, Olesen KKW et al.. “Twenty-Year Temporal Trends in Risk of Ischemic Stroke in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study.” Diabetes care (2022). PMID: 35876649 ↗

    L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  178. [178]

    Aslam AA, Baksh RA, Pape SE et al.. “Diabetes and Obesity in Down Syndrome Across the Lifespan: A Retrospective Cohort Study Using U.K. Electronic Health Records.” Diabetes care (2022). PMID: 36178378 ↗

    L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  179. [179]

    Andrews RC, Cooper AR, Montgomery AA et al.. “Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial.” Lancet (London, England) (2011). PMID: 21705068 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  180. [180]

    Aschner P, Chan J, Owens DR et al.. “Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.” Lancet (London, England) (2012). PMID: 22683131 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  181. [181]

    Thomsen MN, Skytte MJ, Samkani A et al.. “Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial.” Diabetologia (2022). PMID: 34993571 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  182. [182]

    Sanchez-Rangel E, Gunawan F, Jiang L et al.. “Reversibility of brain glucose kinetics in type 2 diabetes mellitus.” Diabetologia (2022). PMID: 35247067 ↗

    L4TRIAL_NONRANDOMCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  183. [183]

    Nanayakkara N, Curtis AJ, Heritier S et al.. “Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses.” Diabetologia (2020). PMID: 33313987 ↗

    L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  184. [184]

    Yapanis M, James S, Craig ME et al.. “Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35094087 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  185. [185]

    Qi L, Chen Y. “Circulating Bile Acids as Biomarkers for Disease Diagnosis and Prevention.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36374935 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
  186. [186]

    Fiorentino TV, Marini MA, Succurro E et al.. “One-Hour Postload Hyperglycemia: Implications for Prediction and Prevention of Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2018). PMID: 30020454 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  187. [187]

    Li K, Liao X, Wang K et al.. “Myonectin Predicts the Development of Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29161407 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  188. [188]

    Sakhaee K, Maalouf NM, Sinnott B. “Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22466339 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  189. [189]

    Galvez-Fernandez M, Powers M, Grau-Perez M et al.. “Urinary Zinc and Incident Type 2 Diabetes: Prospective Evidence From the Strong Heart Study.” Diabetes care (2022). PMID: 36134919 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  190. [190]

    Li Y, Tian J, Hou T et al.. “Association Between Age at Diabetes Diagnosis and Subsequent Incidence of Cancer: A Longitudinal Population-Based Cohort.” Diabetes care (2024). PMID: 38237119 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  191. [191]

    Bril F, Cusi K. “Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.” Diabetes care (2017). PMID: 28223446 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment
  192. [192]

    Steven S, Hollingsworth KG, Small PK et al.. “Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes.” Diabetes care (2015). PMID: 26628414 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  193. [193]

    Brinkhues S, Dukers-Muijrers NHTM, Hoebe CJPA et al.. “Social Network Characteristics Are Associated With Type 2 Diabetes Complications: The Maastricht Study.” Diabetes care (2018). PMID: 29907582 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  194. [194]

    Deetman PE, Kwakernaak AJ, Bakker SJ et al.. “Low-normal free thyroxine confers decreased serum bilirubin in type 2 diabetes mellitus.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23638994 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
  195. [195]

    Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D et al.. “METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes.” European journal of endocrinology (2018). PMID: 29535168 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
  196. [196]

    Andersen M, Glintborg D. “Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT?” European journal of endocrinology (2018). PMID: 29921567 ↗

    L5OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  197. [197]

    Vrbikova J, Hill M, Bendlova B et al.. “Incretin levels in polycystic ovary syndrome.” European journal of endocrinology (2008). PMID: 18511472 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  198. [198]

    de Araújo IM, Salmon CE, Nahas AK et al.. “Marrow adipose tissue spectrum in obesity and type 2 diabetes mellitus.” European journal of endocrinology (2016). PMID: 27707768 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  199. [199]

    Panidis D, Tziomalos K, Chatzis P et al.. “Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome.” European journal of endocrinology (2013). PMID: 23109645 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  200. [200]

    Hanslik G, Wallaschofski H, Dietz A et al.. “Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry.” European journal of endocrinology (2015). PMID: 26311088 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  201. [201]

    Gustafson D, DiStefano PV, Wang XF et al.. “Circulating small extracellular vesicles mediate vascular hyperpermeability in diabetes.” Diabetologia (2024). PMID: 38489029 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  202. [202]

    Jarosinski MA, Dhayalan B, Rege N et al.. “'Smart' insulin-delivery technologies and intrinsic glucose-responsive insulin analogues.” Diabetologia (2021). PMID: 33710398 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  203. [203]

    Gupta S, Eavey RD, Wang M et al.. “Type 2 diabetes and the risk of incident hearing loss.” Diabetologia (2018). PMID: 30402776 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  204. [204]

    Abd-Alrazaq A, Mohamed SP, Alajlani M et al.. “Performance of AI in Predicting the Progression of Gestational Diabetes to Type 2 Diabetes: Systematic Review and Meta-Analysis.” Journal of medical Internet research (2026). PMID: 42424585 ↗

    L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
  205. [205]

    Simpson TC, Clarkson JE, Worthington HV et al.. “Treatment of periodontitis for glycaemic control in people with diabetes mellitus.” The Cochrane database of systematic reviews (2022). PMID: 35420698 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  206. [206]

    Cashmore BA, Cooper TE, Evangelidis NM et al.. “Education programmes for people with chronic kidney disease and diabetes.” The Cochrane database of systematic reviews (2024). PMID: 39171639 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  207. [207]

    Jeyaraman MM, Al-Yousif NSH, Singh Mann A et al.. “Resveratrol for adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2020). PMID: 31978258 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  208. [208]

    Nield L, Moore HJ, Hooper L et al.. “Dietary advice for treatment of type 2 diabetes mellitus in adults.” The Cochrane database of systematic reviews (2007). PMID: 17636747 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  209. [209]

    Hemmingsen B, Krogh J, Metzendorf MI et al.. “Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2016). PMID: 27101360 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  210. [210]

    Callaghan BC, Little AA, Feldman EL et al.. “Enhanced glucose control for preventing and treating diabetic neuropathy.” The Cochrane database of systematic reviews (2012). PMID: 22696371 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  211. [211]

    Malanda UL, Welschen LM, Riphagen II et al.. “Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin.” The Cochrane database of systematic reviews (2012). PMID: 22258959 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  212. [212]

    Middleton P, Crowther CA. “Reminder systems for women with previous gestational diabetes mellitus to increase uptake of testing for type 2 diabetes or impaired glucose tolerance.” The Cochrane database of systematic reviews (2014). PMID: 24638998 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  213. [213]

    Pan SY, Weng CH, Sheen YJ et al.. “Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study.” Ophthalmology science (2026). PMID: 42383218 ↗

    L3COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment
  214. [214]

    Lai SW, Liao KF. “Herpes zoster as a potential clinical marker of undiagnosed Type 2 diabetes in older adults: a retrospective cohort study.” Family practice (2026). PMID: 42348717 ↗

    L3COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  215. [215]

    Singhai A, Meena R, Joshi R et al.. “Prevalence of metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus in India: A systematic review and meta-analysis.” The Indian journal of medical research (2026). PMID: 42397829 ↗

    L4SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  216. [216]

    Wang J, Chen L, Chen X et al.. “Tracing the clinicodermoscopic and histopathological evolution of acquired reactive perforating collagenosis: a case report.” Frontiers in medicine (2026). PMID: 42383033 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  217. [217]

    Prasad AV, Mathai TS, Balamuralikrishna PTS et al.. “Utility of Pancreatic Perivascular Adipose Tissue as a CT Imaging Biomarker for Diagnosing Type 2 Diabetes.” Diabetes (2026). PMID: 42423517 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  218. [218]

    DeBoer MD, Filipp SL, Gurka MJ. “Use of a Metabolic Syndrome Severity Z Score to Track Risk During Treatment of Prediabetes: An Analysis of the Diabetes Prevention Program.” Diabetes care (2018). PMID: 30275282 ↗

    L2RCTCited in: Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  219. [219]

    Zhang J, Tam WWS, Lu J et al.. “Cognitive Risk Stratification Score in Middle-aged and Older Adults With Type 2 Diabetes: A Cross-Sectional Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39901828 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification
  220. [220]

    Fang F, Lai MY, Huang JJ et al.. “Compensatory Hippocampal Connectivity in Young Adults With Early-Stage Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30817818 ↗

    L3OTHERCited in: Severity, Staging and Risk Stratification
  221. [221]

    Kalavalapalli S, Leiva EG, Lomonaco R et al.. “Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36378995 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification
  222. [222]

    Strickland LR, Guo F, Lok K et al.. “Type 2 diabetes with partial lipodystrophy of the limbs: a new lipodystrophy phenotype.” Diabetes care (2013). PMID: 23423695 ↗

    L3OTHERCited in: Severity, Staging and Risk Stratification
  223. [223]

    Lomonaco R, Bril F, Portillo-Sanchez P et al.. “Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.” Diabetes care (2016). PMID: 26861926 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification
  224. [224]

    Ortiz-Lopez C, Lomonaco R, Orsak B et al.. “Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).” Diabetes care (2012). PMID: 22374640 ↗

    L3OTHERCited in: Severity, Staging and Risk Stratification
  225. [225]

    Hulten E, Bittencourt MS, O'Leary D et al.. “Cardiometabolic risk is associated with atherosclerotic burden and prognosis: results from the partners coronary computed tomography angiography registry.” Diabetes care (2013). PMID: 24130364 ↗

    L2OTHERCited in: Severity, Staging and Risk Stratification
  226. [226]

    Segar MW, Vaduganathan M, Patel KV et al.. “Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score.” Diabetes care (2019). PMID: 31519694 ↗

    L2OTHERCited in: Severity, Staging and Risk Stratification
  227. [227]

    Park SE, Kim WJ, Park SW et al.. “High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria.” European journal of endocrinology (2013). PMID: 23144053 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification
  228. [228]

    Lerchbaum E, Schwetz V, Giuliani A et al.. “Influence of a positive family history of both type 2 diabetes and PCOS on metabolic and endocrine parameters in a large cohort of PCOS women.” European journal of endocrinology (2014). PMID: 24591551 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification
  229. [229]

    Oltmanns KM, Dodt B, Schultes B et al.. “Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients.” European journal of endocrinology (2006). PMID: 16452548 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification
  230. [230]

    Zhou Y, Hu L, Zhuang R et al.. “METRNL represses beta-to-alpha cell trans-differentiation to maintain beta cell function under diabetic metabolic stress in mice.” Diabetologia (2025). PMID: 40495021 ↗

    L5OTHERCited in: Severity, Staging and Risk Stratification
  231. [231]

    Xepapadaki E, Nikdima I, Sagiadinou EC et al.. “HDL and type 2 diabetes: the chicken or the egg?” Diabetologia (2021). PMID: 34255113 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  232. [232]

    Highton PJ, Funnell MP, Gupta P et al.. “Improving medication adherence in type 2 diabetes: strategies for better clinical and economic outcomes.” Diabetologia (2025). PMID: 41315090 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification
  233. [233]

    Yang Y, Wang K. “Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.” Frontiers in pharmacology (2026). PMID: 42389271 ↗

    L5SR_OBSCited in: Severity, Staging and Risk Stratification
  234. [234]

    Alyas JT, Nielsen SF, Buus NH. “Explaining blood pressure reduction heterogeneity in sodium-glucose cotransporter-2 inhibitor trials: a meta-analysis stratified by patient characteristics.” Journal of hypertension (2026). PMID: 42359837 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification
  235. [235]

    Rosenfield RL. “The Search for the Causes of Common Hyperandrogenism, 1965 to Circa 2015.” Endocrine reviews (2024). PMID: 38457123 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification, History and Evolution of Treatment
  236. [236]

    Yan C, Zhao Y, Zhang W et al.. “Baseline levels and dynamic trajectories of fasting C peptide to blood glucose ratio predict the risk of combined vascular damage in type 2 diabetes: a longitudinal cohort study.” Diabetes research and clinical practice (2026). PMID: 42379426 ↗

    L2COHORTCited in: Severity, Staging and Risk Stratification
  237. [237]

    Hussain SI, Jalal AA, Adnan Z et al.. “Efficacy and Safety of Pioglitazone Added to Metformin and SGLT2 Inhibitors in Type 2 Diabetes: An Updated Systematic Review and Meta-analysis.” The Annals of pharmacotherapy (2026). PMID: 42365460 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification
  238. [238]

    Cabaluna ITG, Sulit MVV, Infantado-Alejandro MAJ et al.. “2021 Clinical Practice Guidelines on Periodic Health Examination.” Acta medica Philippina (2026). PMID: 42382929 ↗

    L1GUIDELINECited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies
  239. [239]

    Strojek K, Raz I, Jermendy G et al.. “Factors Associated With Cardiovascular Events in Patients With Type 2 Diabetes and Acute Myocardial Infarction.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26595100 ↗

    L2RCTCited in: Acute Management and Endocrine Emergencies
  240. [240]

    Stähli BE, Nozza A, Schrieks IC et al.. “Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29659887 ↗

    L2RCTCited in: Acute Management and Endocrine Emergencies
  241. [241]

    Vestergaard ET, Jessen N, Møller N et al.. “Unacylated Ghrelin Does Not Acutely Affect Substrate Metabolism or Insulin Sensitivity in Men With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30722063 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies
  242. [242]

    D'Alessio DA, Denney AM, Hermiller LM et al.. “Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18957505 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies
  243. [243]

    Umpierrez GE, Smiley D, Jacobs S et al.. “Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery).” Diabetes care (2011). PMID: 21228246 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  244. [244]

    Novak V, Milberg W, Hao Y et al.. “Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes.” Diabetes care (2013). PMID: 24101698 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, History and Evolution of Treatment
  245. [245]

    Daniele G, Xiong J, Solis-Herrera C et al.. “Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.” Diabetes care (2016). PMID: 27561923 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, History and Evolution of Treatment
  246. [246]

    Schrieks IC, Nozza A, Stähli BE et al.. “Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.” Diabetes care (2018). PMID: 29903845 ↗

    L2RCTCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  247. [247]

    Stirban A, Kotsi P, Franke K et al.. “Acute macrovascular dysfunction in patients with type 2 diabetes induced by ingestion of advanced glycated β-lactoglobulins.” Diabetes care (2012). PMID: 23238657 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies
  248. [248]

    Steven S, Hollingsworth KG, Al-Mrabeh A et al.. “Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders.” Diabetes care (2016). PMID: 27002059 ↗

    L4TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies
  249. [249]

    Bhatt DL, Szarek M, Steg PG et al.. “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.” The New England journal of medicine (2020). PMID: 33200892 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  250. [250]

    Bhatt DL, Szarek M, Pitt B et al.. “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The New England journal of medicine (2020). PMID: 33200891 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  251. [251]

    Scirica BM, Bhatt DL, Braunwald E et al.. “Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.” The New England journal of medicine (2013). PMID: 23992601 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  252. [252]

    Zhong VW, Juhaeri J, Mayer-Davis EJ. “Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2018). PMID: 29386248 ↗

    L3COHORTCited in: Acute Management and Endocrine Emergencies
  253. [253]

    Elbalshy MM, Reynolds AN, Mete E et al.. “Gelatinisation and milling whole-wheat increases postprandial blood glucose: randomised crossover study of adults with type 2 diabetes.” Diabetologia (2021). PMID: 33677626 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies
  254. [254]

    Chang LY, Liao HW, Chen JY et al.. “Enhanced Outcomes in Type 2 Diabetes Patients With Acute Kidney Disease Through Thiazolidinedione.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39535770 ↗

    L3OTHERCited in: Acute Management and Endocrine Emergencies
  255. [255]

    Sereg M, Szappanos A, Toke J et al.. “Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study.” European journal of endocrinology (2009). PMID: 19174533 ↗

    L3OTHERCited in: Acute Management and Endocrine Emergencies
  256. [256]

    Ryskjaer J, Deacon CF, Carr RD et al.. “Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.” European journal of endocrinology (2006). PMID: 16914604 ↗

    L4OTHERCited in: Acute Management and Endocrine Emergencies
  257. [257]

    Pinhas-Hamiel O, Zeitler P. “Acute and chronic complications of type 2 diabetes mellitus in children and adolescents.” Lancet (London, England) (2007). PMID: 17531891 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  258. [258]

    Htoo PT, Tesfaye H, Schneeweiss S et al.. “Effectiveness and safety of empagliflozin: final results from the EMPRISE study.” Diabetologia (2024). PMID: 38509341 ↗

    L3OTHERCited in: Acute Management and Endocrine Emergencies, History and Evolution of Treatment, Complications and Long-term Sequelae
  259. [259]

    Home P. “Cardiovascular outcome trials of glucose-lowering medications: an update.” Diabetologia (2019). PMID: 30607467 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies
  260. [260]

    Assogba FG, Couchoud C, Hannedouche T et al.. “Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011.” Diabetologia (2014). PMID: 24496924 ↗

    L2OTHERCited in: Acute Management and Endocrine Emergencies
  261. [261]

    Cline GW, Naganawa M, Chen L et al.. “Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging.” Diabetologia (2018). PMID: 29721633 ↗

    L4OTHERCited in: Acute Management and Endocrine Emergencies
  262. [262]

    Vinué Á, Navarro J, Herrero-Cervera A et al.. “The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.” Diabetologia (2017). PMID: 28608285 ↗

    L5OTHERCited in: Acute Management and Endocrine Emergencies
  263. [263]

    Rodrigues SN, Guterres BV, Carvalho MTX et al.. “Effects of a Synchronous Telehealth Exercise Program on Clinical, Functional, and Psychosocial Outcomes in Individuals with Type 2 Diabetes Mellitus (RED Study): A Randomized Clinical Trial.” International journal of environmental research and public health (2026). PMID: 42354303 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, History and Evolution of Treatment
  264. [264]

    Suda M, Paul KH, Tripathi U et al.. “Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction.” Endocrine reviews (2024). PMID: 38500373 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  265. [265]

    Dodd JM, Grivell RM, Deussen AR et al.. “Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.” The Cochrane database of systematic reviews (2018). PMID: 30039871 ↗

    L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  266. [266]

    Yang S, Ma L, Zeng J et al.. “Trajectory models of serum creatinine and 28-day mortality in critically ill patients with sepsis complicated by type 2 diabetes mellitus: a cohort study.” Frontiers in endocrinology (2026). PMID: 42416900 ↗

    L3COHORTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  267. [267]

    Jung K, Kim GA, Woo J et al.. “Ursodeoxycholic Acid and Long COVID in Steatotic Liver Disease: A Nationwide Cohort Study.” Clinical and molecular hepatology (2026). PMID: 42263781 ↗

    L3COHORTCited in: Acute Management and Endocrine Emergencies
  268. [268]

    Ngiam JN, Loy EX, Koh MCY et al.. “Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study.” Infectious diseases and therapy (2026). PMID: 42236640 ↗

    L3COHORTCited in: Acute Management and Endocrine Emergencies
  269. [269]

    Tang L, He Y, Qiao Z et al.. “Breaking the barrier: oral tacrolimus plus apremilast rescues acute generalized pustular psoriasis with severe comorbidities-a case report.” Frontiers in immunology (2026). PMID: 42344901 ↗

    L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
  270. [270]

    Kang YM, Giugliano RP, Ran X et al.. “Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial.” Diabetes care (2025). PMID: 40544474 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  271. [271]

    Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R et al.. “Curcumin extract for prevention of type 2 diabetes.” Diabetes care (2012). PMID: 22773702 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History and Prevention
  272. [272]

    Stomby A, Otten J, Ryberg M et al.. “Diet-induced weight loss alters hepatic glucocorticoid metabolism in type 2 diabetes mellitus.” European journal of endocrinology (2020). PMID: 32069218 ↗

    L2RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  273. [273]

    Whipple MO, Pinto AJ, Abushamat LA et al.. “Sex Differences in Physical Activity Among Individuals With Type 2 Diabetes Across the Life Span: A Systematic Review and Meta-analysis.” Diabetes care (2022). PMID: 36044665 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  274. [274]

    Weber MA, Mansfield TA, Cain VA et al.. “Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.” The lancet. Diabetes & endocrinology (2015). PMID: 26620248 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  275. [275]

    Perkovic V, Jardine MJ, Neal B et al.. “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.” The New England journal of medicine (2019). PMID: 30990260 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  276. [276]

    Holman RR, Paul SK, Bethel MA et al.. “10-year follow-up of intensive glucose control in type 2 diabetes.” The New England journal of medicine (2008). PMID: 18784090 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  277. [277]

    Cushman WC, Evans GW, Byington RP et al.. “Effects of intensive blood-pressure control in type 2 diabetes mellitus.” The New England journal of medicine (2010). PMID: 20228401 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  278. [278]

    Ginsberg HN, Elam MB, Lovato LC et al.. “Effects of combination lipid therapy in type 2 diabetes mellitus.” The New England journal of medicine (2010). PMID: 20228404 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  279. [279]

    Santi D, Giannetta E, Isidori AM et al.. “Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis.” European journal of endocrinology (2014). PMID: 25277671 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  280. [280]

    Patel A, MacMahon S, Chalmers J et al.. “Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.” Lancet (London, England) (2007). PMID: 17765963 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  281. [281]

    Garber A, Henry R, Ratner R et al.. “Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.” Lancet (London, England) (2008). PMID: 18819705 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  282. [282]

    Garber AJ, King AB, Del Prato S et al.. “Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.” Lancet (London, England) (2012). PMID: 22521072 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  283. [283]

    Rosenstock J, Lorber DL, Gnudi L et al.. “Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial.” Lancet (London, England) (2010). PMID: 20609970 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  284. [284]

    Muir CA, Wittert GA, Handelsman DJ. “Approach to the Patient: Low Testosterone Concentrations in Men With Obesity.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40052430 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  285. [285]

    Chee YJ, Acharyya S, Liew H et al.. “First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial.” Diabetes, obesity & metabolism (2026). PMID: 42396722 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  286. [286]

    Rieg T, Vallon V. “Development of SGLT1 and SGLT2 inhibitors.” Diabetologia (2018). PMID: 30132033 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  287. [287]

    Ghezzi C, Loo DDF, Wright EM. “Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2.” Diabetologia (2018). PMID: 30132032 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  288. [288]

    Schrauwen P, van Marken Lichtenbelt WD. “Combatting type 2 diabetes by turning up the heat.” Diabetologia (2016). PMID: 27591854 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  289. [289]

    Forrestel AC, Miedlich SU, Yurcheshen M et al.. “Chronomedicine and type 2 diabetes: shining some light on melatonin.” Diabetologia (2016). PMID: 27981356 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  290. [290]

    Zhang Q, Ouyang Y, He S et al.. “The efficacy and safety of Chaihu guizhi ganjiang tang for type 2 diabetes mellitus: a systematic review and meta-analysis.” Frontiers in pharmacology (2026). PMID: 42428496 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  291. [291]

    Jais A, Brüning JC. “Arcuate Nucleus-Dependent Regulation of Metabolism-Pathways to Obesity and Diabetes Mellitus.” Endocrine reviews (2022). PMID: 34490882 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  292. [292]

    Gilbert MP, Pratley RE. “The impact of diabetes and diabetes medications on bone health.” Endocrine reviews (2015). PMID: 25738213 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  293. [293]

    Leach MJ, Kumar S. “Cinnamon for diabetes mellitus.” The Cochrane database of systematic reviews (2012). PMID: 22972104 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  294. [294]

    Pattanittum P, Ngamjarus C, Buttramee F et al.. “Roselle for hypertension in adults.” The Cochrane database of systematic reviews (2021). PMID: 34837382 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  295. [295]

    Ooi CP, Loke SC. “Colesevelam for type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2012). PMID: 23235674 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  296. [296]

    Saboo B, Sabharwal M, Gharia M et al.. “App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes: Prospective Observational Cohort Study.” JMIR diabetes (2026). PMID: 42418692 ↗

    L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  297. [297]

    Huang R, Wang B. “Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis.” The Journal of international medical research (2026). PMID: 42424036 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  298. [298]

    Tian R, Zhou X, Pan J et al.. “Activation of Nrf2 signaling and suppression of oxidative stress-induced neuronal apoptosis: mechanisms for baicalin capsules relieving diabetic encephalopathy.” Frontiers in pharmacology (2026). PMID: 42434129 ↗

    L5OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  299. [299]

    Zhou Y, Huang Y, Ji X et al.. “Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 31822895 ↗

    L1SR_OBSCited in: History and Evolution of Treatment, Prognosis, Natural History and Prevention
  300. [300]

    Errazuriz I, Dube S, Slama M et al.. “Randomized Controlled Trial of a MUFA or Fiber-Rich Diet on Hepatic Fat in Prediabetes.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28323952 ↗

    L1RCTCited in: History and Evolution of Treatment
  301. [301]

    Deng X, Zhang C, Wang P et al.. “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35397165 ↗

    L1RCTCited in: History and Evolution of Treatment
  302. [302]

    Bokhari S, Plummer E, Emmerson P et al.. “Glucose counterregulation in advanced type 2 diabetes: effect of β-adrenergic blockade.” Diabetes care (2014). PMID: 25092686 ↗

    L2RCTCited in: History and Evolution of Treatment
  303. [303]

    Hoogendoorn CJ, Krause-Steinrauf H, Uschner D et al.. “Emotional Distress Predicts Reduced Type 2 Diabetes Treatment Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).” Diabetes care (2024). PMID: 38227900 ↗

    L2RCTCited in: History and Evolution of Treatment
  304. [304]

    Ajjan RA, Hensor EMA, Del Galdo F et al.. “Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.” European journal of endocrinology (2022). PMID: 35113805 ↗

    L1RCTCited in: History and Evolution of Treatment
  305. [305]

    Van Raalte DH, van Genugten RE, Eliasson B et al.. “The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.” European journal of endocrinology (2014). PMID: 24421302 ↗

    L1RCTCited in: History and Evolution of Treatment
  306. [306]

    Maxwell JD, Carter HH, Hellsten Y et al.. “Seven-day remote ischaemic preconditioning improves endothelial function in patients with type 2 diabetes mellitus: a randomised pilot study.” European journal of endocrinology (2019). PMID: 31614332 ↗

    L1RCTCited in: History and Evolution of Treatment
  307. [307]

    Park JS, Cho MH, Nam JS et al.. “Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.” European journal of endocrinology (2010). PMID: 20961967 ↗

    L2RCTCited in: History and Evolution of Treatment
  308. [308]

    Fang FS, Gong YP, Li CL et al.. “Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.” European journal of endocrinology (2014). PMID: 24694876 ↗

    L1RCTCited in: History and Evolution of Treatment
  309. [309]

    Tuomilehto J, Lindström J, Eriksson JG et al.. “Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.” The New England journal of medicine (2001). PMID: 11333990 ↗

    L1RCTCited in: History and Evolution of Treatment
  310. [310]

    Zhao G, Bhatia D, Jung F et al.. “Risk of type 2 diabetes mellitus in women with prior hypertensive disorders of pregnancy: a systematic review and meta-analysis.” Diabetologia (2021). PMID: 33409572 ↗

    L1SR_OBSCited in: History and Evolution of Treatment, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  311. [311]

    Han LY, Wu QH, Jiao ML et al.. “Associations between single-nucleotide polymorphisms (+45T>G, +276G>T, -11377C>G, -11391G>A) of adiponectin gene and type 2 diabetes mellitus: a systematic review and meta-analysis.” Diabetologia (2011). PMID: 21638131 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  312. [312]

    Keech A, Simes RJ, Barter P et al.. “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.” Lancet (London, England) (2005). PMID: 16310551 ↗

    L1RCTCited in: History and Evolution of Treatment
  313. [313]

    Chiasson JL, Josse RG, Gomis R et al.. “Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.” Lancet (London, England) (2002). PMID: 12086760 ↗

    L1RCTCited in: History and Evolution of Treatment
  314. [314]

    Gaede P, Vedel P, Parving HH et al.. “Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.” Lancet (London, England) (1999). PMID: 10030326 ↗

    L1RCTCited in: History and Evolution of Treatment
  315. [315]

    Gallwitz B, Rosenstock J, Rauch T et al.. “2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.” Lancet (London, England) (2012). PMID: 22748821 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  316. [316]

    Yan H, Liu J, Zhang Z et al.. “Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial.” Diabetologia (2026). PMID: 41735586 ↗

    L1RCTCited in: History and Evolution of Treatment
  317. [317]

    Drenthen LCA, de Baaij JHF, Rodwell L et al.. “Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial.” Diabetologia (2023). PMID: 37922013 ↗

    L1RCTCited in: History and Evolution of Treatment
  318. [318]

    Cao J, Yan W, Ma X et al.. “Insulin-like Growth Factor 2 mRNA-Binding Protein 2-a Potential Link Between Type 2 Diabetes Mellitus and Cancer.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34061963 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  319. [319]

    Tokoro MF, Mita T, Osonoi Y et al.. “An evening chronotype is associated with the incidence and progression of diabetic retinopathy in people with type 2 diabetes mellitus: a cohort study.” Diabetologia (2025). PMID: 41134330 ↗

    L2COHORTCited in: History and Evolution of Treatment
  320. [320]

    Tobias DK, Gaskins AJ, Missmer SA et al.. “History of infertility and risk of type 2 diabetes mellitus: a prospective cohort study.” Diabetologia (2015). PMID: 25596853 ↗

    L2COHORTCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  321. [321]

    Scairati R, Auriemma RS, Di Meglio S et al.. “Risk Assessment of Diabetes Mellitus During and After Pregnancy in Women With Prolactinomas.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38693775 ↗

    L4OTHERCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  322. [322]

    Pokharel P, Bellinge JW, Dalgaard F et al.. “Vitamin K1 Intake and Incident Diabetes in the Danish Diet, Cancer, and Health Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37235778 ↗

    L2OTHERCited in: History and Evolution of Treatment
  323. [323]

    Yland JJ, Huybrechts KF, Wesselink AK et al.. “Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus.” Diabetes care (2024). PMID: 39042587 ↗

    L2OTHERCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  324. [324]

    Batterham RL, Cummings DE. “Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery.” Diabetes care (2016). PMID: 27222547 ↗

    L5OTHERCited in: History and Evolution of Treatment
  325. [325]

    Ipsen EØ, Madsen KS, Chi Y et al.. “Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2020). PMID: 33210751 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  326. [326]

    Nield L, Summerbell CD, Hooper L et al.. “WITHDRAWN: Dietary advice for the prevention of type 2 diabetes mellitus in adults.” The Cochrane database of systematic reviews (2016). PMID: 26790033 ↗

    L5SR_OBSCited in: History and Evolution of Treatment
  327. [327]

    Pappas Y, Wei I, Car J et al.. “Computer-assisted versus oral-and-written family history taking for identifying people with elevated risk of type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2011). PMID: 22161431 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  328. [328]

    Steinsbekk A, Rygg LØ, Lisulo M et al.. “WITHDRAWN: Group based diabetes self-management education compared to routine treatment, waiting list control or no intervention for people with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2015). PMID: 26125655 ↗

    L5SR_OBSCited in: History and Evolution of Treatment
  329. [329]

    Semlitsch T, Engler J, Siebenhofer A et al.. “(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2020). PMID: 33166419 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  330. [330]

    Wullaert A, van Loo G, Heyninck K et al.. “Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond.” Endocrine reviews (2007). PMID: 17431229 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  331. [331]

    Tamir TT, Zegeye AF, Tekeba B et al.. “Global evidence on risk factors for the progression of gestational diabetes to type 2 diabetes: an umbrella review of systematic reviews and meta-analyses.” Diabetology & metabolic syndrome (2026). PMID: 42304503 ↗

    L2SR_OBSCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  332. [332]

    Salgado-Castillo C, García-Mera C, Hernández-Leal MJ et al.. “Mapping research trends in shared decision-making for type 2 diabetes mellitus: a bibliometric study.” Frontiers in health services (2026). PMID: 42291693 ↗

    L5SR_OBSCited in: History and Evolution of Treatment
  333. [333]

    Chlebek C, Bussberg V, Narain NR et al.. “Baseline serum metabolites predict fractures in individuals who were Black and had type 2 diabetes.” Frontiers in endocrinology (2026). PMID: 42312207 ↗

    L2RCTCited in: History and Evolution of Treatment
  334. [334]

    Thu SYW, Patnaik S, Shih YH. “Yoga and High-Intensity Interval Training Show Comparable Effects on HbA1c in Type 2 Diabetes: A Systematic Review and Preliminary Pilot Network Meta-Analysis in Adult Populations.” Healthcare (Basel, Switzerland) (2026). PMID: 42354561 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  335. [335]

    Liu S, Gao Z, Wang J et al.. “A bibliometric analysis of research on the anti-obesity effects of curcumin from 2006 to 2025: knowledge structure, research hotspots, and evolution of frontiers.” Frontiers in nutrition (2026). PMID: 42293211 ↗

    L5SR_OBSCited in: History and Evolution of Treatment
  336. [336]

    Soria-Contreras DC, Wang S, Liu J et al.. “Lifetime history of gestational diabetes and cognitive function in parous women in midlife.” Diabetologia (2024). PMID: 39240352 ↗

    L2OTHERCited in: History and Evolution of Treatment
  337. [337]

    Gan Y, Chen M, Xiao Z et al.. “Nonlinear association between serum insulin, visceral fat area, and kidney function in female with type 2 diabetes: a retrospective study.” Frontiers in endocrinology (2026). PMID: 42305269 ↗

    L2COHORTCited in: History and Evolution of Treatment
  338. [338]

    Yang M, Liu R, Li S et al.. “Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes.” Diabetes care (2012). PMID: 23275352 ↗

    L2RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  339. [339]

    Özcan B, Neggers SJ, Miller AR et al.. “Does des-acyl ghrelin improve glycemic control in obese diabetic subjects by decreasing acylated ghrelin levels?” European journal of endocrinology (2013). PMID: 23864339 ↗

    L1RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  340. [340]

    Pittas AG, Lau J, Hu FB et al.. “The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17389701 ↗

    L2SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  341. [341]

    Salley KE, Wickham EP, Cheang KI et al.. “Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society.” The Journal of clinical endocrinology and metabolism (2007). PMID: 18056778 ↗

    L1SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  342. [342]

    Mahmoudieh L, Amiri M, Rahmati M et al.. “Idiopathic Hirsutism and Metabolic Status: A Population-based Prospective Cohort Study.” The Journal of clinical endocrinology and metabolism (2022). PMID: 36125321 ↗

    L2COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  343. [343]

    Pistrosch F, Matschke JB, Schipp D et al.. “Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.” Diabetologia (2021). PMID: 34495376 ↗

    L1RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  344. [344]

    DeBoer MD, Gurka MJ, Woo JG et al.. “Severity of the metabolic syndrome as a predictor of type 2 diabetes between childhood and adulthood: the Princeton Lipid Research Cohort Study.” Diabetologia (2015). PMID: 26380985 ↗

    L2COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  345. [345]

    Misra A, Khurana L. “Obesity and the metabolic syndrome in developing countries.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18987276 ↗

    L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  346. [346]

    Buch A, Marcus Y, Shefer G et al.. “Approach to Obesity in the Older Population.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34406394 ↗

    L5OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  347. [347]

    Chen J, Yuan S, Fu T et al.. “Gastrointestinal Consequences of Type 2 Diabetes Mellitus and Impaired Glycemic Homeostasis: A Mendelian Randomization Study.” Diabetes care (2023). PMID: 36800530 ↗

    L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  348. [348]

    Hartstra AV, Bouter KE, Bäckhed F et al.. “Insights into the role of the microbiome in obesity and type 2 diabetes.” Diabetes care (2015). PMID: 25538312 ↗

    L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  349. [349]

    Jobanputra R, Sargeant JA, Plekhanova T et al.. “The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Diabetes/metabolism research and reviews (2026). PMID: 42319968 ↗

    L1SR_MA_RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  350. [350]

    Hoang T, Kim J. “Efficacy and Safety of Probiotics, Prebiotics, and Synbiotics: An Umbrella Review of Systematic Reviews and Meta-Analysis of Randomized Controlled Trials.” Nutrition reviews (2026). PMID: 42289829 ↗

    L1SR_MA_RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  351. [351]

    Paz-Barba M, Muñoz Garcia A, de Winter TJJ et al.. “Apolipoprotein L genes are novel mediators of inflammation in beta cells.” Diabetologia (2023). PMID: 37924378 ↗

    L5OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  352. [352]

    Bruno RM, Penno G, Daniele G et al.. “Type 2 diabetes mellitus worsens arterial stiffness in hypertensive patients through endothelial dysfunction.” Diabetologia (2012). PMID: 22411135 ↗

    L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  353. [353]

    Liu Q, Tang B, Zhu Z et al.. “A genome-wide cross-trait analysis identifies shared loci and causal relationships of type 2 diabetes and glycaemic traits with polycystic ovary syndrome.” Diabetologia (2022). PMID: 35771237 ↗

    L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  354. [354]

    Raghavan S, Porneala B, McKeown N et al.. “Metabolic factors and genetic risk mediate familial type 2 diabetes risk in the Framingham Heart Study.” Diabetologia (2015). PMID: 25619168 ↗

    L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  355. [355]

    Garcia-Ravelo KF, Martagon AJ, Galán-Ramírez GA et al.. “Association between perceived stress and metabolic parameters: a systematic review and meta-analysis.” Diabetology & metabolic syndrome (2026). PMID: 42365351 ↗

    L2SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  356. [356]

    Liu Y, Yang M, Liao Y et al.. “Global research trends, reporting and handling of missing data in observational studies of type 2 diabetes mellitus with mild cognitive impairment from 2020 to 2025: a systematic review.” Frontiers in endocrinology (2026). PMID: 42199803 ↗

    L5SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  357. [357]

    Smith RL, Soeters MR, Wüst RCI et al.. “Metabolic Flexibility as an Adaptation to Energy Resources and Requirements in Health and Disease.” Endocrine reviews (2018). PMID: 29697773 ↗

    L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  358. [358]

    Orozco LJ, Buchleitner AM, Gimenez-Perez G et al.. “Exercise or exercise and diet for preventing type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2008). PMID: 18646086 ↗

    L1SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  359. [359]

    Song R, Hu W, Cheng R et al.. “Association Between Circulating Levels of C1q/TNF-Related Protein-9 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37029975 ↗

    L3SR_OBSCited in: Complications and Long-term Sequelae
  360. [360]

    Hsiao YY, Chen YY, Kuo MJ et al.. “SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39998428 ↗

    L2COHORTCited in: Complications and Long-term Sequelae
  361. [361]

    Hong S, Park JH, Han K et al.. “Association Between Obesity and Cardiovascular Disease in Elderly Patients With Diabetes: A Retrospective Cohort Study.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34597374 ↗

    L2COHORTCited in: Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  362. [362]

    Wijnen M, Olsson DS, van den Heuvel-Eibrink MM et al.. “Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study.” European journal of endocrinology (2017). PMID: 29046325 ↗

    L2COHORTCited in: Complications and Long-term Sequelae
  363. [363]

    Cho J, Woo S, Hwang SH et al.. “A Multimodal Predictive Model for Chronic Kidney Disease and Its Association With Vascular Complications in Patients With Type 2 Diabetes: Model Development and Validation Study in South Korea and the U.K.” Diabetes care (2025). PMID: 40590639 ↗

    L2OTHERCited in: Complications and Long-term Sequelae
  364. [364]

    Kaze AD, Ndumele CE, Martin SS et al.. “Visit-to-Visit Variability in Lipid Levels and Risk of Incident Heart Failure in Adults With Type 2 Diabetes.” Diabetes care (2025). PMID: 40227864 ↗

    L2OTHERCited in: Complications and Long-term Sequelae
  365. [365]

    Mazzone T, Chait A, Plutzky J. “Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies.” Lancet (London, England) (2008). PMID: 18502305 ↗

    L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae
  366. [366]

    Hayes AJ, Leal J, Gray AM et al.. “UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.” Diabetologia (2013). PMID: 23793713 ↗

    L2OTHERCited in: Complications and Long-term Sequelae
  367. [367]

    Hu X, Guo F. “Amino Acid Sensing in Metabolic Homeostasis and Health.” Endocrine reviews (2021). PMID: 33053153 ↗

    L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  368. [368]

    Batista PG, Dos Santos Silva RRA, Montenegro MV et al.. “GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2026). PMID: 42387250 ↗

    L1SR_OBSCited in: Complications and Long-term Sequelae
  369. [369]

    Rosenzweig JL, Ferrannini E, Grundy SM et al.. “Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18664543 ↗

    L1GUIDELINECited in: Prognosis, Natural History and Prevention
  370. [370]

    Zhang Y, Tan H, Tang J et al.. “Effects of Vitamin D Supplementation on Prevention of Type 2 Diabetes in Patients With Prediabetes: A Systematic Review and Meta-analysis.” Diabetes care (2020). PMID: 33534730 ↗

    L1SR_OBSCited in: Prognosis, Natural History and Prevention
  371. [371]

    Frye RL, August P, Brooks MM et al.. “A randomized trial of therapies for type 2 diabetes and coronary artery disease.” The New England journal of medicine (2009). PMID: 19502645 ↗

    L1RCTCited in: Prognosis, Natural History and Prevention
  372. [372]

    Zandbergen AA, Lamberts SW, Janssen JA et al.. “Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I.” European journal of endocrinology (2006). PMID: 16868143 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis, Natural History and Prevention
  373. [373]

    Bo S, Gentile L, Castiglione A et al.. “C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up.” European journal of endocrinology (2012). PMID: 22577110 ↗

    L2COHORTCited in: Prognosis, Natural History and Prevention
  374. [374]

    Lundgrin EL, Hatipoglu B. “Trending Modalities in Type 2 Diabetes Prevention.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39998920 ↗

    L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention
  375. [375]

    Al-Aubaidy HA, Jelinek HF. “Oxidative DNA damage and obesity in type 2 diabetes mellitus.” European journal of endocrinology (2011). PMID: 21436346 ↗

    L3OTHERCited in: Prognosis, Natural History and Prevention
  376. [376]

    Ferreira JP, Lamiral Z, Xhaard C et al.. “Circulating plasma proteins and new-onset diabetes in a population-based study: proteomic and genomic insights from the STANISLAS cohort.” European journal of endocrinology (2020). PMID: 32567559 ↗

    L2OTHERCited in: Prognosis, Natural History and Prevention
  377. [377]

    Mayer-Davis EJ, Lawrence JM, Dabelea D et al.. “Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012.” The New England journal of medicine (2017). PMID: 28402773 ↗

    L2OTHERCited in: Prognosis, Natural History and Prevention
  378. [378]

    Yoon NA, Diano S. “Hypothalamic glucose-sensing mechanisms.” Diabetologia (2021). PMID: 33544170 ↗

    L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention
  379. [379]

    Rodrigues de Oliveira Filho J, Bregion PB, Juca RH et al.. “GERD remission and safety profile of Single Anastomosis Sleeve Ileal (SASI) bypass vs sleeve gastrectomy (SG): a systematic review and meta-analysis.” Surgical endoscopy (2026). PMID: 42377474 ↗

    L2SR_OBSCited in: Prognosis, Natural History and Prevention
  380. [380]

    Karczewski D, Karczewski T, Olsen M. “Glycated Hemoglobin and Prediabetes: A Systematic Review of HbA1c Thresholds for Type 2 Diabetes Prevention.” Journal of clinical medicine (2026). PMID: 42355858 ↗

    L2SR_OBSCited in: Prognosis, Natural History and Prevention
  381. [381]

    Palomba S, Falbo A, Zullo F et al.. “Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.” Endocrine reviews (2008). PMID: 19056992 ↗

    L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  382. [382]

    Nield L, Summerbell CD, Hooper L et al.. “Dietary advice for the prevention of type 2 diabetes mellitus in adults.” The Cochrane database of systematic reviews (2008). PMID: 18646120 ↗

    L1SR_OBSCited in: Prognosis, Natural History and Prevention
  383. [383]

    Al Nofal A, Benkhadra K, Abbas A et al.. “A Systematic Review Supporting the Clinical Practice Guidelines on the Management of Preexisting Diabetes and Pregnancy.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40652449 ↗

    L1GUIDELINECited in: Special Populations, Pregnancy and Fertility
  384. [384]

    Zhong VW, Juhaeri J, Cole SR et al.. “Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2017). PMID: 28716781 ↗

    L3COHORTCited in: Special Populations, Pregnancy and Fertility
  385. [385]

    Karstoft K, Clark MA, Jakobsen I et al.. “Glucose effectiveness, but not insulin sensitivity, is improved after short-term interval training in individuals with type 2 diabetes mellitus: a controlled, randomised, crossover trial.” Diabetologia (2017). PMID: 28842722 ↗

    L1RCTCited in: Special Populations, Pregnancy and Fertility
  386. [386]

    Bao W, Yeung E, Tobias DK et al.. “Long-term risk of type 2 diabetes mellitus in relation to BMI and weight change among women with a history of gestational diabetes mellitus: a prospective cohort study.” Diabetologia (2015). PMID: 25796371 ↗

    L2COHORTCited in: Special Populations, Pregnancy and Fertility
  387. [387]

    Joham AE, Ranasinha S, Zoungas S et al.. “Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24081730 ↗

    L4OTHERCited in: Special Populations, Pregnancy and Fertility
  388. [388]

    Retnakaran R, Shah BR. “Role of Type 2 Diabetes in Determining Retinal, Renal, and Cardiovascular Outcomes in Women With Previous Gestational Diabetes Mellitus.” Diabetes care (2016). PMID: 27821407 ↗

    L3OTHERCited in: Special Populations, Pregnancy and Fertility
  389. [389]

    Yoshida Y, Chen Z, Baudier RL et al.. “Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women.” Diabetes care (2021). PMID: 34475032 ↗

    L2OTHERCited in: Special Populations, Pregnancy and Fertility
  390. [390]

    Morrison KM, Xu L, Tarnopolsky M et al.. “Screening for dysglycemia in overweight youth presenting for weight management.” Diabetes care (2012). PMID: 22271926 ↗

    L4OTHERCited in: Special Populations, Pregnancy and Fertility
  391. [391]

    Kramer CK, Swaminathan B, Hanley AJ et al.. “Each degree of glucose intolerance in pregnancy predicts distinct trajectories of β-cell function, insulin sensitivity, and glycemia in the first 3 years postpartum.” Diabetes care (2014). PMID: 25231898 ↗

    L2OTHERCited in: Special Populations, Pregnancy and Fertility
  392. [392]

    Pellitero S, Reverter JL, Granada ML et al.. “Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.” European journal of endocrinology (2009). PMID: 19304869 ↗

    L4OTHERCited in: Special Populations, Pregnancy and Fertility
  393. [393]

    Vitezova A, Zillikens MC, van Herpt TT et al.. “Vitamin D status and metabolic syndrome in the elderly: the Rotterdam Study.” European journal of endocrinology (2014). PMID: 25468955 ↗

    L4OTHERCited in: Special Populations, Pregnancy and Fertility
  394. [394]

    Awa WL, Fach E, Krakow D et al.. “Type 2 diabetes from pediatric to geriatric age: analysis of gender and obesity among 120,183 patients from the German/Austrian DPV database.” European journal of endocrinology (2012). PMID: 22645200 ↗

    L4OTHERCited in: Special Populations, Pregnancy and Fertility
  395. [395]

    Sparks JR, Ghildayal N, Hivert MF et al.. “Lifestyle interventions in pregnancy targeting GDM prevention: looking ahead to precision medicine.” Diabetologia (2022). PMID: 35150287 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy and Fertility
  396. [396]

    Ravnsborg T, Andersen LL, Trabjerg ND et al.. “First-trimester multimarker prediction of gestational diabetes mellitus using targeted mass spectrometry.” Diabetologia (2016). PMID: 26818149 ↗

    L3OTHERCited in: Special Populations, Pregnancy and Fertility
  397. [397]

    Lloyd M, Morton J, Teede H et al.. “Long-term cost-effectiveness of implementing a lifestyle intervention during pregnancy to reduce the incidence of gestational diabetes and type 2 diabetes.” Diabetologia (2023). PMID: 36932207 ↗

    L5OTHERCited in: Special Populations, Pregnancy and Fertility
  398. [398]

    Derse TK, Kide DM, Asgai AS et al.. “Metabolic trajectory from gestational to type 2 diabetes mellitus: a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42218942 ↗

    L2SR_OBSCited in: Special Populations, Pregnancy and Fertility
  399. [399]

    Tieu J, Middleton P, Crowther CA et al.. “Preconception care for diabetic women for improving maternal and infant health.” The Cochrane database of systematic reviews (2017). PMID: 28799164 ↗

    L1SR_OBSCited in: Special Populations, Pregnancy and Fertility
  400. [400]

    Han S, Middleton P, Shepherd E et al.. “Different types of dietary advice for women with gestational diabetes mellitus.” The Cochrane database of systematic reviews (2017). PMID: 28236296 ↗

    L1SR_OBSCited in: Special Populations, Pregnancy and Fertility
  401. [401]

    Öner MÖ, Aslan F, Binici S et al.. “Safety and Metabolic Outcomes of Three-Port Laparoscopic Sleeve Gastrectomy Without Liver Retractor: A 2000-Patient Retrospective Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356128 ↗

    L4COHORTCited in: Special Populations, Pregnancy and Fertility
  402. [402]

    Zhang H, Chen D, Song Q et al.. “Staged antibiotic-loaded cement-based reconstruction versus flap-based reconstruction for complex diabetic foot defects in patients with osteoporosis: a retrospective cohort study.” Frontiers in surgery (2026). PMID: 42245312 ↗

    L2COHORTCited in: Special Populations, Pregnancy and Fertility
  403. [403]

    Travis LM, Kimbrough DW, Samineni AV et al.. “Effect of hemoglobin A1c levels on 30-day complications after elective anterior cervical discectomy and fusion: a retrospective cohort study.” Journal of spine surgery (Hong Kong) (2026). PMID: 42158068 ↗

    L2COHORTCited in: Special Populations, Pregnancy and Fertility
  404. [404]

    Jang K, Zeitler PS. “Prediabetes in children and adolescents: what do we need to know?” Annals of pediatric endocrinology & metabolism (2026). PMID: 42415555 ↗

    L5OTHERCited in: Special Populations, Pregnancy and Fertility

Revision History

All updates applied to this page

Loading revisions…